The mTOR gene in humans produces the protein known as mTOR (mammalian target of rapamycin). A serine/threonine protein kinase called mTOR controls transcription, protein synthesis, cell motility, growth, and proliferation in living things. The phosphatidylinositol 3-kinase-related kinase protein family includes mTOR. Growth factors and amino acids are just two examples of the input from upstream pathways that mTOR integrates.Additionally, mTOR detects cellular energy, oxygen, and nutrient levels. In human diseases like diabetes, obesity, depression, and some cancers, the mTOR pathway is dysregulated. By collaborating with its intracellular receptor FKBP12, rapamycin inhibits mTOR. The mTOR FKBP12-Rapamycin Binding (FRB) domain is directly contacted by the FKBP12-rapamycin complex, which inhibits mTOR activity.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V70257 | mTOR inhibitor-13 | 1144075-44-4 | mTOR inhibitor-13 (compound 9g) is an arylurea-based compound and is a potent and specific mTOR inhibitor (antagonist) with IC50 of 0.29 nM. |
|
V79112 | mTOR inhibitor-14 | mTOR inhibitor-14 (compound 14c) is a potent mTOR inhibitor. | |
|
V70242 | mTOR/HDAC-IN-1 | 2815286-02-1 | mTOR/HDAC-IN-1 (Compound 50) is a selective dual (bifunctional) inhibitor of mTOR and HDAC, with IC50 of 0.49 and 0.91 nM for mTOR and HDAC1, respectively. |
|
V77738 | mTORC1-IN-1 | mTORC1-IN-1 (compound T1) is a rapamycin homolog (rapalog) and selective mTORC1 inhibitor. | |
|
V70258 | mTORC1-IN-2 | 2974368-96-0 | mTORC1-IN-2 (compound H3) is a NO donor compound that alleviates vasodilation and myocardial hypoxic injury. |
|
V2317 | NV-5138 | 2095886-80-7 | NV-5138 (NV 5138; NV5138) is a novel, selective, orally bioactive and brain/CNS-active mTORC1 (mammalian target of rapamycin complex 1) activator. |
|
V70227 | NV-5138 hydrochloride | 2639392-70-2 | NV-5138 HCl is a leucine analogue and the first selective, orally bioactive mTORC1 agonist in the brain that binds to Sestrin2. |
|
V2957 | Onatasertib (CC-223) | 1228013-30-6 | Onatasertib (CC-223; CC223) is a potent, selective, and orally bioavailable inhibitor of mTOR (mammalian target of rapamycin) kinase with anticancer activity. |
|
V0189 | OSI-027 (ASP-4786, CERC-006, AEVI-006) | 936890-98-1 | OSI-027 (formerly known as ASP4786; AEVI006; CERC006) is a novel, potent, selective, orally bioavailable and ATP-competitive dual inhibitor of mTORC1 (mammalian target of rapamycin 1) and mTORC2with potential anticancer activity. |
|
V0199 | Palomid 529 (P-529, SG00-529) | 914913-88-5 | Palomid 529 (also called P529, SG00-529), developed byPaloma Pharmaceuticals, isanovel and potent inhibitor of mTOR (mammalian target of rapamycin) with potential antitumor activity. |
|
V3440 | PQR-620 | 1927857-56-4 | PQR620 is a novel, potent, selective and brain penetrant inhibitor ofmTORC1/2 which plays a fundamental role in cell proliferation, differentiation, growth and survival. |
|
V70231 | PQR626 | 1927857-98-4 | PQR626 is a rapamycin analogue. |
|
V70248 | QL-IX-55 | 1223002-54-7 | QL-IX-55 is an ATP competitive mTORC1/2 inhibitor (antagonist) with IC50 of 50, 50 and 10-50 nM for human mTORC1, yeast mTORC1 and 2 respectively. |
|
V0174 | Rapamycin (Sirolimus; AY22989) | 53123-88-9 | Rapamycin (also known as Sirolimus; AY-22989), a natural macrocyclic lactone isolated from the bacterium Streptomyces hygroscopicus, is a specific and potent mTOR inhibitor with IC50 of ~0.1 nM in HEK293 cells. |
|
V0184 | Ridaforolimus (Deforolimus, MK8669, AP23573) | 572924-54-0 | Ridaforolimus (also known as deforolimus, AP-23573; MK-8669) is a novel, potent,investigational and selective mTOR inhibitor withsignificant antitumor effects. |
|
V70253 | RMC-4529 | 2250059-27-7 | RMC-4529 has IC50 of 1.0 nM for p-4E-BP1-(T37/46) in mTOR kinase cellular assays. |
|
V70238 | RMC-4627 | 2250059-52-8 | RMC-4627 is a selective mTORC1 inhibitor that activates/agonizes 4EBP1 and inhibits tumor growth. |
|
V70228 | RMC-6272 (RM-006) | 2382769-46-0 | RMC-6272 (RM-006) is a dual-space, selective mTORC1 inhibitor (antagonist) with >10-fold greater inhibitory effect on mTORC1 than mTORC2. |
|
V2082 | Salidroside (Rhodioloside) | 10338-51-9 | Salidroside (Rhodioloside), a naturally occuring phenylpropanoid glycoside isolated from Rhodiola rosea, has been reported to have a broad spectrum of pharmacological properties such as anticancer, antidepressant and anxiolytic effects. |
|
V0185 | Sapanisertib (NK128; MLN0128; TAK228) | 1224844-38-5 | Sapanisertib (NK-128; MLN-0128; TAK-228) is a novel, potent, orally bioavailable and selective inhibitor of mTOR (mammalian target of rapamycin) with potential anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
